Abstract: [Abstract]???Objective???To explore the relationship between renin-angiotensin system (RAS) blockers and plasma level of adiponectin (APN) in patients with metabolic syndrome (Mets).??Methods?? Fifty-three patients with Mets were randomized into control group (n=23), angiotensin-convertingenzyme inhibitor (ACEI) group (benidipine, 5mg /d,n=15) and angiotensinll recepter blockers（ARB）group (candesartan,4mg/d,n=15)，and were given4-week treatment. Twenty-three patients, who were avoiding application related drugs affecting the RAS for four weeks, were used as control. The values of plasma APN, fasting blood glucose (FBG), fasting insulin (FINS), triglyceride (TG), high-density lipoprotein cholesterol (HDLC), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), creatinine(CR), aspartate aminotransferase (ALT), bilirubin (BIL) and insulin resistance index (HOMA-IR) were detected and compared before and after treatment.???Results??? The levels of FBG and LDL-C were significantly decreased after treatment than those before treatment in ACEI group. The level of CR was significantly lower after treatment than that before treatment in ARB group (P＜0.05). The plasma APN level was significantly higher after treatment compared to that before treatment in ACEI and ARB groups (P＜0.01).There were no significant differences in the values of FINS，HOMA-IR，TC，ALT and BIL between'before and after treatment' in three groups (P＞0.05). The levels of CR, TC, ALT and BIL before treatment were influencing factors for the APN level. The levels of FBG and TC after treatment were influencing factors for the APN level.??Conclusion?? APN may serve as potential therapeutic targets for treating Mets and its related complications by ACEI and ARB.

Key words: renin-angiotensin system, angiotensin-converting enzyme inhibitors, adiponectin, Metabolic syndrome X, receptor, angiotensin, type2, 血管紧张素Ⅱ1型受体拮抗剂